Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 4:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 25,184 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PRE Clear all

Conditions: Lymphoma, Non-Hodgkin Lymphoma, NHL, Hematologic Malignancies, Lymphoid Malignancies
Interventions: Vysis LSI MYC Break Apart Rearrangement Probe Kit, Venetoclax, VIP152, Prednisone, PET, EKG, ECHO, CT neck chest, abdomen, and pelvis, MRI, Bone marrow aspiration/Biopsy; Device · Drug · Diagnostic Test + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Kidney Cancer
Interventions: sorafenib tosylate; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Prostate Cancer, Prostate Cancer Adenocarcinoma, Non-Metastatic
Interventions: Cabozantinib, Radical Prostatectomy; Drug · Procedure
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions: Ipilimumab, Nivolumab; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Depressive Symptoms
Interventions: Brief Interpersonal Psychotherapy - Adolescent Skills Training (B-IPT-AST), Services as usual (SAU); Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 13 Years to 17 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: LPL Deficiency
Interventions: alipogene tiparvovec, Prednisolone, Cyclosporins, Mycophenolate mofetil; Drug
Lead sponsor: UniQure Biopharma B.V.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Metastatic Castration Resistant Prostate Cancer
Interventions: TAS3681; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 11
States / cities: Sacramento, California • Sarasota, Florida • Tampa, Florida + 8 more

Conditions: Skin Lesion, Skin Abnormalities, Sebaceous Hyperplasia
Interventions: Nano-Pulse Stimulation Device; Device
Lead sponsor: Pulse Biosciences, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 5
States / cities: Sacramento, California • San Mateo, California • Chestnut Hill, Massachusetts + 2 more

Conditions: Atherosclerosis
Interventions: R-alpha lipoic acid; Dietary Supplement
Lead sponsor: Oregon State University; Other
Eligibility: 50 Years to 70 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Graft Versus Host Disease
Interventions: sirolimus; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Influenza Immunization
Interventions: Quadrivalent Influenza mRNA Vaccine MRT5413, Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza High-Dose Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 682 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 28
States / cities: Chula Vista, California • Gardena, California • Long Beach, California + 24 more

Conditions: Plantar Fasciitis
Interventions: Treatment Cohort, Control Cohort; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Stroke
Interventions: Deficit-fields to reduce error, Deficit-fields to expand range of motion, Deficit-fields to improve function; Behavioral
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 100 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Ulcerative Colitis, FMT, Fecal Microbiota Transplant
Interventions: Metronidazole, Placebo, Vancomycin, Fecal Microbiota Transplantation; Drug · Biological
Lead sponsor: Ari M Grinspan; Other
Eligibility: 18 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer
Interventions: Fluzone Trivalent; Biological
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Cancer
Interventions: Online Survey, Chatbot prototype, Open to Options (O2O) Program; Behavioral
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Non-Squamous Non-Small Cell Lung Cancer
Interventions: MEGF0444A, bevacizumab, carboplatin, paclitaxel, placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 20
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Santa Monica, California + 17 more

Conditions: End Stage Renal Disease, Renal Anemia, Chronic Kidney Diseases
Interventions: Anemia Controller; Other
Lead sponsor: Renal Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Prevention
Interventions: Descovy; Drug
Lead sponsor: Vivent Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Denver, Colorado • St Louis, Missouri • Milwaukee, Wisconsin

Conditions: Obstructive Sleep Apnea
Interventions: Donepezil, placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 70 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: San Diego, California

Conditions: Prehypertension (elevated Blood Pressure) or Hypertension
Interventions: H1 receptor blockade: 540 mg (Allegra), H2 receptor blockade: 40 mg (Pepcid AC); Genetic
Lead sponsor: California Baptist University; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Riverside, California

Conditions: Head and Neck Cancer
Interventions: Isocaloric and iso-nitrogenous standard enteral tube feeds, Nestle IMPACT AR; Dietary Supplement
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Contraception, Inhalation of Nitrous Oxide
Interventions: In-office Transcervical Sterilization (Essure®), Standard Oral pain medications, Intramuscular Ketorolac, Placebo pills, Oxygen, Nitrous Oxide; Procedure · Drug · Other
Lead sponsor: University of New Mexico; Other
Eligibility: 21 Years and older · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Aging
Interventions: Protein, Placebo; Dietary Supplement · Other
Lead sponsor: Florida State University; Other
Eligibility: 60 Years to 75 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Tallahassee, Florida

Search by objective public record fields.

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer

Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer

Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL

Improving Mood for Adolescents Through Teaming With End-Users in Routine Care (The iMATTER Project)

Alipogene Tiparvovec for the Treatment of LPLD Patients

Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer

Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia

The Role of R-Alpha Lipoic Acid in the Treatment of Atherosclerotic Vascular Disease

Sirolimus as Secondary Therapy in Chronic Graft-Versus-Host Disease Not Responding To Prior Treatment

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older

The Effects of Terrain Variation on Intrinsic Foot Musculature in Healthy Individuals and Individuals With Plantar Fasciitis

Deficit Fields for Stroke Recovery

Refined Fecal Microbiota Transplantation (FMT) for Ulcerative Colitis (UC)

A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision

Patient-centered Development of the Cancer Support Community's Open to Options ®Chatbot Program

Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)

Assessment of an Anemia Model Predictive Controller for Anemia Management in Hemodialysis Patients

Telehealth as a Modality to Increase the Uptake of PrEP Services in Black and Latino: "e-PrEP"

The Impact of Arousal Threshold in Obstructive Sleep Apnea

Effect of Aerobic Exercise with Blood Flow Restriction on Post-exercise Hypotension in Young Adults: the Role of Histamine Receptors

Perioperative Nutritional Optimization in Head and Neck Cancer Patients

Nitrous Oxide for Pain Management During In-office Transcervical Sterilization

Efficacy of Pre-sleep or Post-exercise Protein During 12 Weeks of Resistance Exercise Training